156 related articles for article (PubMed ID: 35569008)
1. Design and synthesis of five-membered heterocyclic derivatives of istradefylline with comparable pharmacological activity.
Wang Y; Wang H; Xu H; Zheng Z; Meng Z; Xu Z; Li J; Xue M
Chem Biol Drug Des; 2022 Oct; 100(4):534-552. PubMed ID: 35569008
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A
Ohno Y; Suzuki M; Asada H; Kanda T; Saki M; Miyagi H; Yasunaga M; Suno C; Iwata S; Saito JI; Uchida S
Mol Pharmacol; 2023 Jun; 103(6):311-324. PubMed ID: 36894319
[TBL] [Abstract][Full Text] [Related]
3. The belated US FDA approval of the adenosine A
Chen JF; Cunha RA
Purinergic Signal; 2020 Jun; 16(2):167-174. PubMed ID: 32236790
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
6. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacological profile of the A2A receptor antagonist istradefylline.
Saki M; Yamada K; Koshimura E; Sasaki K; Kanda T
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):963-72. PubMed ID: 23812646
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A
Rohilla S; Bansal R; Kachler S; Klotz KN
Bioorg Chem; 2019 Jun; 87():601-612. PubMed ID: 30933785
[TBL] [Abstract][Full Text] [Related]
9. A New Series of 1,3-Dimethylxanthine Based Adenosine A
Rohilla S; Bansal R; Chauhan P; Kachler S; Klotz KN
Curr Drug Discov Technol; 2021; 18(5):e26082020185360. PubMed ID: 32860362
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.
Yamada K; Kobayashi M; Shiozaki S; Ohta T; Mori A; Jenner P; Kanda T
Psychopharmacology (Berl); 2014 Jul; 231(14):2839-49. PubMed ID: 24488405
[TBL] [Abstract][Full Text] [Related]
11. Istradefylline - a first generation adenosine A
Jenner P; Mori A; Aradi SD; Hauser RA
Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
[No Abstract] [Full Text] [Related]
12. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
13. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
14. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Müller T
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
[TBL] [Abstract][Full Text] [Related]
15. The safety of istradefylline for the treatment of Parkinson's disease.
Müller T
Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
[TBL] [Abstract][Full Text] [Related]
16. Selective Deuteration Improves the Affinity of Adenosine A
Hok L; Vianello R
J Chem Inf Model; 2023 May; 63(10):3138-3149. PubMed ID: 37155356
[TBL] [Abstract][Full Text] [Related]
17. The Pharmacological Potential of Adenosine A
Mori A; Chen JF; Uchida S; Durlach C; King SM; Jenner P
Molecules; 2022 Apr; 27(7):. PubMed ID: 35408767
[TBL] [Abstract][Full Text] [Related]
18. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
Mizuno Y; Kondo T;
Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.
Pinna A
CNS Drugs; 2014 May; 28(5):455-74. PubMed ID: 24687255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
